Iris Jacobs

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Elena Santagostino, U. Martinowitz, Toshko Lissitchkov et al. · Blood · 2016 · 210 citations · Full text

Medicine, Hematology, Molecular Biology +12

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Elena Santagostino, Claude Négrier, Robert Klamroth et al. · Blood · 2012 · 172 citations · Full text

Medicine, Hematology, Pharmacokinetics +16

About The Cochrane Collaboration (Cochrane Review Groups (CRGs)).

Raimondo Ascione, JP Casas, Joshua Cleland et al. · 2011 · 126 citations

Public Health, Biostatistics, Evidence-based Practice +11

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Timothy Craig, Avner Reshef, H Henry Li et al. · The Lancet · 2023 · 113 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks

Timothy Craig, Bruce L. Zuraw, Hilary Longhurst et al. · The Journal of Allergy and Clinical Immunology In Practice · 2019 · 97 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13